| Cadila Healthcare has received phase-I clinical trial permission from the DCGI for ZYOG1, a novel GLP-1 agonist, designed and developed at the company's research centre using a unique platform technology. ZYOG1 is a novel, oral anti-diabetic molecule. |
Monday, June 21, 2010
Cadila Healthcare receives phase-I clinical trial permission from DCGI
Subscribe to:
Post Comments (Atom)
Indian Rupee Exchange Rate
No comments:
Post a Comment